Andres Hernandez-Abreu
Internal Medicine · Brooklyn, NYNPI 1518929009
Payments from drug & device makers
Across 380 payments — averaging $19.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$1K
- Lilly USA, LLC$751
- Novartis$724
- AstraZeneca$606
- Merck$600
- AbbVie$588
- plus $3K from 20 others
What the payments were for
- Food & beverage$7,37699%
- Education$411%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 58 | $1,001 |
| Lilly USA, LLC | 40 | $751 |
| Novartis | 35 | $724 |
| AstraZeneca | 27 | $606 |
| Merck | 29 | $600 |
| AbbVie(2 entities) | 36 | $588 |
| Exact Sciences | 22 | $529 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 32 | $496 |
| Boehringer Ingelheim | 19 | $382 |
| GSK | 19 | $375 |
| Amarin Pharma, Inc. | 12 | $316 |
| Novo Nordisk | 14 | $310 |
| Amgen | 7 | $140 |
| Kowa Pharmaceuticals America, Inc. | 6 | $103 |
| Ironwood Pharmaceuticals, Inc | 5 | $88 |
| Medtronic | 1 | $77 |
| Xeris Pharmaceuticals, Inc. | 3 | $57 |
| Johnson & Johnson | 2 | $44 |
| Ardelyx, Inc. | 2 | $43 |
| Sanofi-aventis U.S. LLC | 2 | $41 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $34 |
| Neurocrine Biosciences, Inc. | 1 | $31 |
| Astellas Pharma US Inc | 1 | $26 |
| Philips North America LLC | 1 | $24 |
| Alnylam Pharmaceuticals Inc. | 1 | $17 |
| Otsuka America Pharmaceutical, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,417 in reported general payments places this provider in the 90th percentile of 9,771 internal medicine providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 249 | $204,395 |
| TrulicityDulaglutide | 148 | $159,996 |
| FarxigaDapagliflozin Propanediol | 196 | $145,494 |
| OzempicSemaglutide | 134 | $126,525 |
| TradjentaLinagliptin | 161 | $108,255 |
| EliquisApixaban | 150 | $103,402 |
| JanuviaSitagliptin Phosphate | 104 | $93,811 |
| JanumetSitagliptin Phos/Metformin Hcl | 85 | $63,239 |
| KerendiaFinerenone | 74 | $50,219 |
| LinzessLinaclotide | 84 | $49,750 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 116 | $35,522 |
| EntrestoSacubitril/Valsartan | 36 | $33,015 |
| XareltoRivaroxaban | 44 | $32,661 |
| MounjaroTirzepatide | 18 | $31,301 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 41 | $25,402 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Jentadueto, Combivent Respimat | $382 | $345,296461 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $751 | $191,297166 claims |
| MerckJanuvia, Janumet, Janumet Xr | $600 | $174,992209 claims |
| AstraZenecaFarxiga, Symbicort | $606 | $151,576224 claims |
| Novo NordiskOzempic, Rybelsus | $310 | $141,005148 claims |
| AbbVieLinzess, Combigan | $588 | $55,479105 claims |
| BayerKerendia | $1,001 | $50,21974 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $375 | $48,931102 claims |
| NovartisEntresto | $724 | $33,01536 claims |
| Johnson & JohnsonXarelto | $44 | $32,66144 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $496 | $24,29542 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Brooklyn
- Bruce BergerBrooklyn$3.4M
- Nelly CohenBrooklyn$2.8M
- Jorge SerjeBrooklyn$1.3M
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- David DoveEast Hampton$12.3M
- Robert CupeloEast Syracuse$10.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.